Emerging therapeutics for myasthenia gravis
Publication
, Conference
Punga, AR; Kaminski, HJ; Guptill, JT
Published in: Current Clinical Neurology
January 1, 2018
At no time in the history of myasthenia gravis has there been a time of greater therapeutic development. This situation likely stems from the well-defined pathophysiology of MG, which has made target identification relatively straightforward for drug development in the pharmaceutical industry and academic laboratories. Financial incentives to develop therapies for rare diseases have also been a positive factor. The present review assesses conventional treatments and drugs in preclinical and clinical trials
Duke Scholars
Published In
Current Clinical Neurology
DOI
EISSN
2524-4043
ISSN
1559-0585
Publication Date
January 1, 2018
Volume
0
Start / End Page
319 / 333
Citation
APA
Chicago
ICMJE
MLA
NLM
Punga, A. R., Kaminski, H. J., & Guptill, J. T. (2018). Emerging therapeutics for myasthenia gravis. In Current Clinical Neurology (Vol. 0, pp. 319–333). https://doi.org/10.1007/978-3-319-73585-6_20
Punga, A. R., H. J. Kaminski, and J. T. Guptill. “Emerging therapeutics for myasthenia gravis.” In Current Clinical Neurology, 0:319–33, 2018. https://doi.org/10.1007/978-3-319-73585-6_20.
Punga AR, Kaminski HJ, Guptill JT. Emerging therapeutics for myasthenia gravis. In: Current Clinical Neurology. 2018. p. 319–33.
Punga, A. R., et al. “Emerging therapeutics for myasthenia gravis.” Current Clinical Neurology, vol. 0, 2018, pp. 319–33. Scopus, doi:10.1007/978-3-319-73585-6_20.
Punga AR, Kaminski HJ, Guptill JT. Emerging therapeutics for myasthenia gravis. Current Clinical Neurology. 2018. p. 319–333.
Published In
Current Clinical Neurology
DOI
EISSN
2524-4043
ISSN
1559-0585
Publication Date
January 1, 2018
Volume
0
Start / End Page
319 / 333